Clarke C E, Speller J M
Department of Neurology, City Hospital NHS Trust, Dudley Road, Birmingham, West Midlands, United Kingdom, B18 7QH.
Cochrane Database Syst Rev. 2000;1999(2):CD001515. doi: 10.1002/14651858.CD001515.
To compare the efficacy and safety of adjuvant lisuride therapy versus placebo in patients with Parkinson's disease, already established on levodopa and suffering from motor complications.
Electronic searches of MEDLINE, EMBASE and the Cochrane Controlled Trials Register. Handsearching of the neurology literature as part of the Cochrane Movement Disorders Group's strategy. Examination of the reference lists of identified studies and other reviews. Contact with Cambridge Laboratories and Roche Products Limited.
Randomised controlled trials of lisuride versus placebo in patients with a clinical diagnosis of idiopathic Parkinson's disease and long-term complications of levodopa therapy.
Data was to be abstracted independently by each author and differences settled by discussion.
No randomised controlled trials comparing lisuride with placebo in advanced Parkinson's disease with motor complications were found.
REVIEWER'S CONCLUSIONS: Well designed randomised controlled trials demonstrating efficacy and safety are required before the use of lisuride in later Parkinson's disease can be supported.
比较阿朴吗啡治疗与安慰剂治疗对已确诊帕金森病且正在接受左旋多巴治疗并伴有运动并发症患者的疗效和安全性。
对MEDLINE、EMBASE和Cochrane对照试验注册库进行电子检索。作为Cochrane运动障碍小组策略的一部分，对手检神经学文献进行检索。查阅已识别研究和其他综述的参考文献列表。与剑桥实验室和罗氏产品有限公司联系。
关于阿朴吗啡与安慰剂对比治疗临床诊断为特发性帕金森病且有左旋多巴治疗长期并发症患者的随机对照试验。
每位作者独立提取数据，通过讨论解决分歧。
未发现比较阿朴吗啡与安慰剂治疗晚期帕金森病伴运动并发症的随机对照试验。
在支持将阿朴吗啡用于晚期帕金森病之前，需要设计良好的随机对照试验来证明其疗效和安全性。
